SCHEMBL2297881

SCHEMBL2297881

Cc1cc(NC(=O)c2ccccc2C(=O)c2ccc3nc(NC(=O)O)[nH]c3c2)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 5/20 0.58
▸ BRAF P15056 5/20 0.58
▸ ALDH1A1 P00352 4/20 0.54
▸ MAPT P10636 3/20 0.54
▸ CYP2C9 P11712 3/20 0.54
▸ LMNA P02545 3/20 0.54
▸ HTT P42858 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ ABL1 P00519 3/20 0.50
▸ KDR P35968 3/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ ABCC4 O15439 1/20 0.50
▸ USP2 O75604 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ XIAP P98170 1/20 0.48
▸ MAPK1 P28482 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2299039 0.90 RAF1 (0.54) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL2300095 0.90 RAF1 (0.54) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL3471881 0.87 RAF1 (0.59) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL1467653 0.85 MAPT (0.51) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL2357955 0.85 RAF1 (0.63) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL2300130 0.85 RAF1 (0.57) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL3473662 0.85 RAF1 (0.59) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL3475822 0.85 RAF1 (0.59) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL2299292 0.83 RAF1 (0.55) RAF1BRAFALDH1A1MAPTCYP2C9
SCHEMBL3474868 0.83 RAF1 (0.60) RAF1BRAFALDH1A1MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101759-B1 METHODS OF USING MEK INHIBITORS EXELIXIS INC (US) 2018-10-10 — — EP claimed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US claimed
EP-2139484-B9 METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA EXELIXIS INC (US) 2014-06-11 — — EP disclosed
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 — — EP disclosed
EP-2139483-B1 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-09-18 — — EP disclosed
EP-2139484-B1 METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA EXELIXIS INC (US) 2013-07-17 — — EP disclosed
US-7999006-B2 Anticancer agents; mitogen-activated protein kinases (MEK) EXELIXIS, INC. (US) 2011-08-16 — — US disclosed
Send feedback